AlphaQuest LLC Trims Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

AlphaQuest LLC lowered its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 63.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,142 shares of the biotechnology company’s stock after selling 12,668 shares during the quarter. AlphaQuest LLC’s holdings in Arcturus Therapeutics were worth $121,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Arcturus Therapeutics by 10.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 846 shares during the period. SG Americas Securities LLC increased its stake in Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after buying an additional 3,705 shares during the period. Spire Wealth Management increased its stake in Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after buying an additional 10,746 shares during the period. BNP Paribas Financial Markets increased its stake in Arcturus Therapeutics by 954.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,831 shares of the biotechnology company’s stock worth $367,000 after buying an additional 14,330 shares during the period. Finally, Verition Fund Management LLC purchased a new position in Arcturus Therapeutics in the 3rd quarter worth about $420,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Wells Fargo & Company reduced their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Canaccord Genuity Group dropped their target price on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Finally, HC Wainwright dropped their target price on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $59.20.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $13.73 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 1 year low of $12.75 and a 1 year high of $45.00. The stock has a market cap of $372.36 million, a price-to-earnings ratio of -6.18 and a beta of 2.96. The firm’s 50-day moving average is $16.40 and its two-hundred day moving average is $18.19.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. On average, equities analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.